EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Metastatic Non‐Myofibroblastic Sarcoma Harbouring EML4‐ALK Fusion—Dramatic Response to ALK Tyrosine Kinase Inhibitors and Development of Resistance Mutations

Isabella Wilson iD, Min Qiu, Malinda Itchins, Bin Wang, Min Li Huang, Peter Grimison

Cancer Reports · 2024

DOI: 10.1002/cnr2.2164 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cancer Reports, 2024. Verfasst von Isabella Wilson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, Australia. Hauptthemen laut MEDLINE: Oncogene Proteins, Fusion, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Anaplastic Lymphoma Kinase. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anaplastic lymphoma kinase ( ALK ) rearrangements are rare in non‐myofibroblastic sarcoma and there is limited data on the efficacy of ALK tyrosine kinase inhibitors (TKIs) and mechanisms of resistance in these patients. Case A 58 year‐old man with metastatic non‐myofibroblastic sarcoma was found to have an EML4‐ALK fusion on molecular sequencing. After progression on first line systemic therapy with doxorubicin, the patient received alectinib, a second generation ALK inhibitor, and had a marked clinical and radiological response. He progressed after 5 months of treatment. Repeat lung biopsy identified the emergence of an ALK I1171N resistance mutation. He was then treated with lorlatinib, again with rapid clinical improvement and significant partial radiological response. He progressed after 4 months, at which time a repeat lung biopsy identified a new ALK kinase domain mutation G1202R. The patient was subsequently treated with chemotherapy, though unfortunately died shortly after due to rapidly progressive disease.

Conclusion

This case report adds to a body of evidence demonstrating the potential transformative response to targeted therapy in non‐lung solid organ tumours harbouring ALK fusions. This is the first description tracking the development of resistance mutations in a patient with non‐myofibroblastic sarcoma and questions the utility of the presence of G1202R mutation as a marker of lorlatinib sensitivity in non‐lung ALK rearranged tumours, contrary to experience in lung cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oncogene Proteins, FusionDrug Resistance, NeoplasmProtein Kinase InhibitorsAnaplastic Lymphoma KinaseSarcomaLactamsMutationLactams, MacrocyclicHumansMaleMiddle AgedPyrazolesFatal OutcomeAminopyridinesCarbazolesPiperidinesTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

alectinibanaplastic lymphoma kinaselorlatinibsarcomatyrosine kinase inhibitors

Substanzen

Oncogene Proteins, FusionEML4-ALK fusion protein, humanProtein Kinase InhibitorsAnaplastic Lymphoma KinaselorlatinibLactamsLactams, MacrocyclicalectinibALK protein, humanPyrazoles

Autor:innen und Institutionen

  • Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, Australia.
  • Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
  • Sydpath, St Vincent's Hospital, Sydney, Australia.
  • St Vincent's Clinical School, University of New South Wales, Sydney, Australia.
  • Department of Medical Oncology, Royal North Shore Hospital, Sydney, Australia.
  • Kinghorn Centre for Cancer Genomics Medicine, Garvan Institute of Medical Research, Sydney, Australia.

ORCID-Profile: Isabella Wilson

Zitieren

APA

Wilson, I., Qiu, M., Itchins, M., Wang, B., Huang, M. L., & Grimison, P. (2024). Metastatic Non‐Myofibroblastic Sarcoma Harbouring EML4‐ALK Fusion—Dramatic Response to ALK Tyrosine Kinase Inhibitors and Development of Resistance Mutations. Cancer Reports. https://doi.org/10.1002/cnr2.2164

Vancouver

Wilson I, Qiu M, Itchins M, Wang B, Huang ML, Grimison P. Metastatic Non‐Myofibroblastic Sarcoma Harbouring EML4‐ALK Fusion—Dramatic Response to ALK Tyrosine Kinase Inhibitors and Development of Resistance Mutations. Cancer Reports. 2024. doi:10.1002/cnr2.2164

BibTeX
@article{Wilson2024,
  author = {Wilson, Isabella and Qiu, Min and Itchins, Malinda and Wang, Bin and Huang, Min Li and Grimison, Peter},
  title = {Metastatic Non‐Myofibroblastic Sarcoma Harbouring EML4‐ALK Fusion—Dramatic Response to ALK Tyrosine Kinase Inhibitors and Development of Resistance Mutations},
  journal = {Cancer Reports},
  year = {2024},
  doi = {10.1002/cnr2.2164}
}
Kostenlos starten →